Literature DB >> 11585761

Macrophages orchestrate the immune response to tumor cell death.

M J Gough1, A A Melcher, A Ahmed, M R Crittenden, D S Riddle, E Linardakis, A N Ruchatz, L M Emiliusen, R G Vile.   

Abstract

The mechanisms by which the immune system distinguishes normal developmental cell death from pathological immunogenic cell killing are central to effective cancer immunotherapy. Using HSVtk suicide gene therapy, we showed that macrophages can distinguish between tumor cells dying through classical apoptosis and tumor cells engineered to die through nonapoptotic mechanisms, resulting in secretion of either immunosuppressive cytokines (interleukin 10 and transforming growth factor beta) or inflammatory cytokines (tumor necrosis factor alpha or interleukin 1beta), respectively. Additionally heat shock protein 70 acts as one component of a bimodal alarm signal that activates macrophages in the presence of stressful, immunogenic tumor cell killing. These differential responses of macrophages can also be used to vaccinate mice against tumor challenge, using adoptive transfer, as well as to cure mice of established tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585761

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Cytokine gene expression profile in monocytic cells after a co-culture with epithelial cells.

Authors:  Libor Kolesar; Eva Brabcova; Eliska Thorburn; Alena Sekerkova; Irena Brabcova; Marcela Jaresova; Ondrej Viklicky; Ilja Striz
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

2.  Restoration of dysregulated CC chemokine signaling for monocyte/macrophage chemotaxis in head and neck squamous cell carcinoma patients by neem leaf glycoprotein maximizes tumor cell cytotoxicity.

Authors:  Krishnendu Chakraborty; Anamika Bose; Tathagata Chakraborty; Koustav Sarkar; Shyamal Goswami; Smarajit Pal; Rathindranath Baral
Journal:  Cell Mol Immunol       Date:  2010-07-12       Impact factor: 11.530

3.  Adenosine promotes alternative macrophage activation via A2A and A2B receptors.

Authors:  Balázs Csóka; Zsolt Selmeczy; Balázs Koscsó; Zoltán H Németh; Pál Pacher; Peter J Murray; Diane Kepka-Lenhart; Sidney M Morris; William C Gause; S Joseph Leibovich; György Haskó
Journal:  FASEB J       Date:  2011-09-16       Impact factor: 5.191

4.  Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.

Authors:  Nelson C Di Paolo; Sebastian Tuve; Shaoheng Ni; Karl Erik Hellström; Ingegerd Hellström; André Lieber
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

Review 5.  Intratumoral immunotherapy: using the tumour against itself.

Authors:  Marka R Crittenden; Uma Thanarajasingam; Richard G Vile; Michael J Gough
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

6.  Regulation of HSP70 on activating macrophages using PDT-induced apoptotic cells.

Authors:  Feifan Zhou; Da Xing; Wei R Chen
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

Review 7.  Facets of heat shock protein 70 show immunotherapeutic potential.

Authors:  Stephen M Todryk; Michael J Gough; A Graham Pockley
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

8.  Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine.

Authors:  David G Casey; Joanne Lysaght; Tharappel James; Andrew Bateman; Alan A Melcher; Stephen M Todryk
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

9.  Suppression of PLCbeta2 by endotoxin plays a role in the adenosine A(2A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype.

Authors:  Stan Grinberg; Gyorgy Hasko; Dianqing Wu; Samuel Joseph Leibovich
Journal:  Am J Pathol       Date:  2009-10-22       Impact factor: 4.307

Review 10.  Contribution of macrophages to fetomaternal immunological tolerance.

Authors:  P Parasar; N Guru; N R Nayak
Journal:  Hum Immunol       Date:  2021-03-11       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.